Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery.

"table s4); ld bdf5 bd5 2 apo structure crystallographic data"

"The authors declare the following competing financial interest(s): We disclose that Felix Calderon, Raquel Gabarro and Jacob Bush are employees of GSK. GSK provided some of the SGC Tool Compounds to support the lab work. This work was in part supported by funding from GSK through the Pipeline Futures Group."

"C.N.R. thanks the BBSRC for studentship support (BB/M011151/1). N.G.J., J.C.M. and A.J.W were supported by GSK through the Pipeline Futures Group and a Fellowship from a Research Council United Kingdom Grand Challenges Research Funder under grant agreement ‘A Global Network for Neglected Tropical Diseases’ grant number MR/P027989/1. This work was part-funded by the Wellcome Trust [ref: 204829] through the Centre for Future Health (CFH) at the University of York. J.L.C. and S.J.C. thank the EPSRC and GlaxoSmithKline for studentship support (EP/R513295/1). S.J.C. thanks St Hugh’s College, Oxford, for research support. The authors acknowledge their colleagues in The Bioscience Technology Facility of the University of York, including Dr. Jared Cartwright and Rebecca Preece for protein production, and Dr. Andrew Leech for carrying out SEC-MALLS. The authors are grateful to Sam Hart and Dr. Johan Turkenburg for their assistance in X-ray data collection and analysis. They thank the DIAMOND Light Source for access to beamline I04 (proposal number mx-18598) that contributed to the results presented here. They also thank Dr Raymond Hui and the Structural Genomics Consortium for gifting compounds and plasmids. The authors declare the following competing financial interest(s): We disclose that Felix Calderon, Raquel Gabarro and Jacob Bush are employees of GSK. GSK provided some of the SGC Tool Compounds to support the lab work. This work was in part supported by funding from GSK through the Pipeline Futures Group."